Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification
MetadataShow full item record
NTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD), involving a triad of laboratory and bone abnormalities, and tissue calcifications, are associated with dismal hard-outcomes. AREAS COVERED: In two comprehensive articles, we review contemporary and future pharmacological options for treatment of phosphate (P) imbalance (this part 1) and hyperparathyroidism (part 2), taking into account CKD-accelerated atheromatosis/atherosclerosis and/or cardiovascular calcification (CVC) processes. EXPERT OPINION: Improvements in CKD-MBD require an integral approach, addressing all three components of the CKD-MBD triad. Individualization of treatment with P-binders and combinations of anti-parathyroid agents may improve biochemical control with lower incidence of undesirable effects. Isolated biochemical parameters do not accurately reflect calcium or P load or bone activity and do not stratify high cardiovascular risk patients with CKD. Initial guidance is provided on reasonable therapeutic strategies which consider the presence of CVC. This part reflects that although there is not an absolute evidence, many studies point to the need to improve P imbalance while trying to, at least, avoid progression of CVC by restriction of Ca-based P-binders if economically feasible. The availability of new drugs (i.e. inhibitors of intestinal transporters), and studies including early CKD should ultimately lead to clearer and more cost/effective clinical targets for CKD-MBD.
Is part ofExpert Opinion On Pharmacotherapy, 2016, vol. 17, num. 9, p. 1247-1258
European research projects
Showing items related by title, author, creator and subject.
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification Bover, J.; Ureña-Torres, P.; Lloret, MJ.; Ruiz, C.; DaSilva, I.; Diaz-Encarnacion, MM.; Mercado, C.; Mateu, S.; Fernández i Giráldez, Elvira; Ballarin, J. (Taylor & Francis, 2016-07-31)INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are associated with costly complications and dismal hard-outcomes. AREAS COVERED: In two comprehensive articles we review contemporary and future ...
Carmona, Andrés; Agüera, Maria L.; Luna-Ruiz, Carlos; Buendía, Paula; Calleros-Basilio, Laura; García-Jerez, Andrea; Rodríguez-Puyol, Manuel; Arias, Manuel; Arias-Guillen, Marta; Arriba, Gabriel de; Ballarin, José; Bernis, Carmen; Fernández i Giráldez, Elvira; García-Rebollo, Sagrario; Mancha, Javier; Peso, Gloria del; Pérez, Estefanía; Poch, Esteban; Portolés, José M.; Rodríguez-Puyol, Diego; Sánchez-Villanueva, Rafael; Sarró, Felipe; Torres, Armando; Martín-Malo, Alejandro; Aljama, Pedro; Ramírez, Rafael; Carracedo, Júlia (American Physiological Society, 2017-04-01)Patients with Stage 5 chronic kidney disease who are on hemodialysis (HD) remain in a chronic inflammatory state, characterized by the accumulation of uremic toxins that induce endothelial damage and cardiovascular disease ...
Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study Abajo, María; Betriu i Bars, M. Àngels; Arroyo, David; Gracia, Marta; Pino, María Dolores del; Martínez, Isabel; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (Oxford University Press, 2017-08-27)BACK GROUND: The leading cause of premature death in chronic kidney disease (CKD) is cardiovascular disease (CVD), but risk assessment in renal patients is challenging. The aim of the study was to analyse the factors that ...